Developing a new antifungal treatment for drug-resistant infections
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
This study is working on a new treatment for tough fungal infections caused by Candida and Aspergillus that don't respond to current medications, aiming to help patients who have few options left.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prokaryotics, INC. NIH-funded |
| Lab location | 1 site (Union, United States) |
| Project ID | NIH-10907819 on NIH RePORTER |
What this research studies
This research focuses on creating a new antifungal therapy that targets the biosynthesis of Glycosylphosphatidylinositol (GPI) to combat drug-resistant fungal infections caused by Candida and Aspergillus species. The approach involves optimizing the pharmacokinetic properties of new drug analogs and testing their effectiveness in animal models. By addressing the growing issue of azole and echinocandin resistance, this research aims to provide a treatment option for patients who currently have limited or no effective therapies available.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with compromised immune systems, such as those undergoing cancer treatment, organ transplant recipients, or patients with HIV/AIDS.
Not a fit: Patients with fungal infections that are not resistant to current antifungal treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients suffering from multidrug-resistant fungal infections.
How similar studies have performed: While the approach of targeting GPI biosynthesis is innovative, similar research has shown promise in developing antifungal therapies, indicating potential for success.
Where this research is happening
Union, United States
- Prokaryotics, INC. — Union, United States (Active)
Researchers
- Principal investigator: Roemer, Terry — Prokaryotics, INC.
- Study coordinator: Roemer, Terry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.